KDR and Patent ductus arteriosus: To further investigate the potential antitumor role of VEGFR-2, an oral humanized anti-VEGFR-2 vaccine, namely, VXM01, was tested with success in preclinical mouse models [38,160] and in locally advanced PDA patients [42].